Semaglutide Protects Kidneys Across All Risk Categories in People with Type 2 Diabetes and Heart Disease
Post hoc analysis of the SUSTAIN 6 trial showed that once-weekly semaglutide improved kidney disease outcomes across all KDIGO risk categories in patients with type 2 diabetes and cardiovascular disease.
Quick Facts
What This Study Found
Once-weekly semaglutide improved kidney disease outcomes consistently across all KDIGO risk categories in SUSTAIN 6 participants with T2D and cardiovascular disease or high CV risk.
Key Numbers
Post hoc analysis of SUSTAIN 6 trial; kidney outcomes assessed across all KDIGO risk categories; compared once-weekly semaglutide vs. placebo.
How They Did This
Post hoc analysis of the SUSTAIN 6 randomized controlled trial, stratifying participants by KDIGO risk category to assess semaglutide's effects on kidney disease outcomes and KDIGO risk category transitions vs. placebo.
Why This Research Matters
Kidney disease is a leading complication of diabetes. This analysis provides evidence that semaglutide's kidney benefits extend across the full spectrum of kidney disease severity — supporting its use even in patients who already have significant kidney impairment.
The Bigger Picture
GLP-1 receptor agonists are emerging as multi-organ protective agents — not just blood sugar and weight loss drugs. This kidney analysis, combined with cardiovascular data from SUSTAIN 6 and the dedicated renal outcomes trial FLOW, positions semaglutide as a foundational therapy for diabetic patients at cardiorenal risk.
What This Study Doesn't Tell Us
Post hoc analysis — not the primary trial endpoint. SUSTAIN 6 was designed for cardiovascular outcomes, not kidney endpoints. Subgroup analyses may lack power for individual KDIGO categories. Median follow-up of ~2 years may miss long-term kidney effects.
Questions This Raises
- ?How do semaglutide's kidney benefits in SUSTAIN 6 compare to the dedicated FLOW renal outcomes trial?
- ?Should KDIGO guidelines upgrade GLP-1RAs from risk-based to universal recommendation in diabetic kidney disease?
- ?Do higher semaglutide doses (2.4 mg) provide additional kidney protection beyond the 1.0 mg dose studied?
Trust & Context
- Key Stat:
- All KDIGO risk categories Semaglutide showed kidney-protective effects regardless of baseline kidney disease severity in SUSTAIN 6
- Evidence Grade:
- Strong evidence — derived from a large, well-designed RCT (SUSTAIN 6), though the kidney analysis is post hoc rather than a pre-specified primary endpoint.
- Study Age:
- Published in 2024. Builds on SUSTAIN 6 trial data with kidney-focused reanalysis. Complements the 2024 FLOW trial results.
- Original Title:
- Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial.
- Published In:
- Kidney international reports, 9(7), 2006-2015 (2024)
- Authors:
- Tuttle, Katherine R(10), Bain, Stephen C(9), Bosch-Traberg, Heidrun(3), Khunti, Kamlesh, Rasmussen, Søren, Sokareva, Ekaterina, Cherney, David Z
- Database ID:
- RPEP-09416
Evidence Hierarchy
Frequently Asked Questions
Can semaglutide protect the kidneys in people with diabetes?
Yes — this analysis of the SUSTAIN 6 trial found that once-weekly semaglutide improved kidney outcomes in people with type 2 diabetes, regardless of how advanced their kidney disease was at baseline. This adds to growing evidence that GLP-1 drugs benefit the kidneys beyond just controlling blood sugar.
Should people with kidney disease still take semaglutide?
This study suggests that kidney disease is not a reason to avoid semaglutide — in fact, patients across all kidney disease severity levels benefited. Current guidelines already recommend GLP-1 receptor agonists for diabetic patients at kidney risk, and this data further supports that recommendation.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09416APA
Tuttle, Katherine R; Bain, Stephen C; Bosch-Traberg, Heidrun; Khunti, Kamlesh; Rasmussen, Søren; Sokareva, Ekaterina; Cherney, David Z. (2024). Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial.. Kidney international reports, 9(7), 2006-2015. https://doi.org/10.1016/j.ekir.2024.04.028
MLA
Tuttle, Katherine R, et al. "Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial.." Kidney international reports, 2024. https://doi.org/10.1016/j.ekir.2024.04.028
RethinkPeptides
RethinkPeptides Research Database. "Effects of Once-Weekly Semaglutide on Kidney Disease Outcome..." RPEP-09416. Retrieved from https://rethinkpeptides.com/research/tuttle-2024-effects-of-onceweekly-semaglutide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.